Zhou JH, Yi QJ, Li MY, Xu Y, Dong Q, Wang CY, Liu HY. Inetetamab combined with tegafur as second-line treatment for human epidermal growth factor receptor-2-positive gastric cancer: A case report. World J Clin Cases 2024; 12(4): 820-827 [PMID: 38322681 DOI: 10.12998/wjcc.v12.i4.820]
Corresponding Author of This Article
Hai-Yan Liu, MD, Doctor, Department of Oncology, The Second Affiliated Hospital of Shandong First Medical University, No. 706 Taishan Street, Tai’an 271000, Shandong Province, China. fylhy1998@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Feb 6, 2024 (publication date) through Oct 23, 2025
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Zhou JH, Yi QJ, Li MY, Xu Y, Dong Q, Wang CY, Liu HY. Inetetamab combined with tegafur as second-line treatment for human epidermal growth factor receptor-2-positive gastric cancer: A case report. World J Clin Cases 2024; 12(4): 820-827 [PMID: 38322681 DOI: 10.12998/wjcc.v12.i4.820]
World J Clin Cases. Feb 6, 2024; 12(4): 820-827 Published online Feb 6, 2024. doi: 10.12998/wjcc.v12.i4.820
Inetetamab combined with tegafur as second-line treatment for human epidermal growth factor receptor-2-positive gastric cancer: A case report
Jing-Hao Zhou, Qi-Jun Yi, Ming-Yan Li, Yan Xu, Qi Dong, Cong-Ying Wang, Hai-Yan Liu
Jing-Hao Zhou, Qi-Jun Yi, Ming-Yan Li, Yan Xu, Qi Dong, Cong-Ying Wang, Hai-Yan Liu, Department of Oncology, The Second Affiliated Hospital of Shandong First Medical University, Tai’an 271000, Shandong Province, China
Author contributions: Liu HY, Zhou JH and Yi QJ conceived, designed and refined the study protocol; Zhou JH contributed to manuscript writing and editing, and data collection; Dong Q and Wang CY contributed to conceptualization and supervision; Xu Y, Li MY and Liu HY revised the manuscript; all authors have read and approved the final manuscript.
Supported bythe Science and Technology Innovation Development Project of Tai’an, No. 2021NS160; and the Medical and Health Science and Technology Development Plan of Shandong Province, No. 202102010647.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest related to this manuscript.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hai-Yan Liu, MD, Doctor, Department of Oncology, The Second Affiliated Hospital of Shandong First Medical University, No. 706 Taishan Street, Tai’an 271000, Shandong Province, China. fylhy1998@163.com
Received: November 6, 2023 Peer-review started: November 6, 2023 First decision: November 16, 2023 Revised: November 22, 2023 Accepted: January 12, 2024 Article in press: January 12, 2024 Published online: February 6, 2024 Processing time: 79 Days and 23.1 Hours
Core Tip
Core Tip: In this paper, we present a case involving a patient with human epidermal growth factor receptor-2 (HER2)-positive gastric cancer who was received oxaliplatin combined with tegafur as the first-line treatment post surgery. The patient was diagnosed with postoperative recurrence of gastric adenocarcinoma. He received inetetamab, an innovative domestically developed anti-HER2 monoclonal antibody, combined with tegafur chemotherapy as the second-line treatment. Evaluation of the efficacy of the second-line treatment revealed that the patient achieved a stable condition. This is significant because We provided a practical reference case for HER2-positive gastric cancer patients who was received inetetamab that is an innovative domestically developed anti-HER2 monoclonal antibody, which may help to provide survival benefits to some extent.
